Six Specialist Consultancy Services. One World-Class Standard.
Every GDI India consultation draws on CAP & CLIA accredited expertise from Genesys Diagnostics Inc., USA. Consultation fee: ₹1,00,000 + 18% GST (₹1,18,000 total) per session.
We bridge the gap between global clinical standards and Indian healthcare, delivering authoritative expert advisory based on CAP & CLIA accredited USA expertise.
Genetic Wellness Consultation
Unlock Your Genetic Blueprint for Lifelong Health
Your DNA contains the most precise health roadmap ever written — and it was written specifically for you. Our Genetic Wellness Consultation decodes your genomic profile to deliver a fully personalised advisory covering diet, supplementation, exercise, and lifestyle — all calibrated to your unique genetic makeup. Stop guessing. Start living with genetic precision.
The Science
Genomic profiling analyses inherited variants affecting metabolism, nutrient absorption, inflammatory response, exercise adaptation, and disease predisposition. GDI's wellness panel examines these markers against an evidence base built over 15+ years of clinical genetics practice, generating actionable, science-backed guidance that no generic health plan can replicate.
Who Should Seek This Consultation
Individuals seeking preventive health optimisation | Those with family history of lifestyle diseases (diabetes, hypertension, obesity) | Corporate wellness programme participants | Athletes seeking genetic performance optimisation | Anyone who wants to stop treating symptoms and start preventing them
What You Receive
- Comprehensive genomic wellness advisory report | Personalised dietary guidance based on genetic profile | Supplement protocol calibrated to your metabolic markers | Lifestyle and exercise action plan | 30-day follow-up advisory session
What You Receive
- Cancer genomic advisory report | Targeted therapy and immunotherapy guidance brief | Hereditary cancer risk assessment | Oncologist liaison communication brief | Referral pathway recommendations
Cancer Diagnostic Advisory
Precision Genomics for Cancer Detection and Targeted Therapy Guidance
Cancer is not one disease — it is hundreds, each with a unique genomic fingerprint. GDI's Cancer Diagnostic Advisory provides expert guidance on molecular genomic profiling for cancer diagnosis, targeted therapy selection, and hereditary cancer risk assessment. When standard diagnostics are not enough, genomic intelligence changes everything.
The Science
Cancer genomics identifies somatic mutations, chromosomal abnormalities, gene expression patterns, and biomarkers that determine which targeted therapies will be most effective for a specific tumour. GDI's FDA-approved testing menu covers solid tumours (lung, breast, colorectal, prostate), haematological malignancies (leukaemia, lymphoma), and hereditary cancer syndromes (BRCA1/2, Lynch syndrome, Li-Fraumeni).
Who Should Seek This Consultation
Cancer patients seeking genomic second opinions | Oncologists requiring molecular profiling guidance | Individuals with strong family history of cancer | Patients considering targeted therapy or immunotherapy | Those who have received inconclusive conventional diagnostic results
Infectious Disease Diagnostic Advisory
Rapid Molecular Guidance for Complex Infectious Disease Management
When infections persist, recur, or resist standard treatment, the answer lies at the molecular level. GDI's Infectious Disease Advisory provides expert guidance on FDA-approved molecular diagnostic panels — delivering pathogen identification, antibiotic resistance profiling, and treatment pathway guidance with the speed and precision that conventional testing cannot match.
Who Should Seek This Consultation
- Patients with complex, persistent, or treatment-resistant infections | Physicians requiring pathogen identification and resistance profiling guidance | Hospitals managing outbreak investigation | Immunocompromised patients requiring rapid diagnosis | Travellers returning with undiagnosed febrile illness
The Science
Molecular PCR (Polymerase Chain Reaction) and Next-Generation Sequencing (NGS) identify pathogens with sensitivity and specificity far exceeding traditional culture methods. Results are available same-day, enabling faster clinical decisions. GDI's panel covers respiratory pathogens, gastrointestinal infections, sexually transmitted infections, rare tropical diseases, and hospital-acquired infections.
What You Receive
- Pathogen identification advisory report | Antibiotic and antiviral resistance guidance | Treatment pathway recommendations | Infection control and management brief | Urgent referral pathway if required
Prenatal & Postnatal Genetic Consultation
Informed Decisions for the Health of Your Child
Every parent deserves to know. GDI's Prenatal & Postnatal Genetic Consultation provides comprehensive expert guidance on chromosomal abnormalities, single-gene disorders, and heritable conditions — giving families the genetic intelligence they need to make informed, empowered decisions at every stage of the journey to parenthood.
The Science
Prenatal genetic testing detects chromosomal aneuploidies (Down syndrome — Trisomy 21, Edwards syndrome — Trisomy 18, Patau syndrome — Trisomy 13), neural tube defects, and single-gene disorders through Non-Invasive Prenatal Testing (NIPT), amniocentesis analysis, chorionic villus sampling interpretation, and carrier screening. Globally, 7.9 million births annually involve serious birth defects — 94% occurring in middle and low-income countries.
Who Should Seek This Consultation
- Expectant mothers — particularly those over 35 | Couples with family history of genetic or chromosomal conditions | Carriers of known genetic mutations considering pregnancy | Those with abnormal ultrasound findings or elevated screening markers | Parents of children with diagnosed genetic conditions planning future pregnancies
What You Receive
Comprehensive prenatal risk assessment report | Condition-specific counselling and guidance | Postnatal genetic management advisory | Family planning and reproductive options brief | Referral pathway to specialist maternal-foetal medicine
Pharmacogenetics & Personalised Medicine Advisory
The Right Medicine. The Right Dose. Based on Your DNA.
DESCRIPTION
Not all medications work the same way for all people — and the reason is written in your genes. GDI's Pharmacogenetics Advisory analyses your genetic profile to identify which medications will be most effective, which carry adverse reaction risk, and what dosing is optimal for your unique biology. Eliminate trial-and-error prescribing. Personalise your medicine.
The Science
Pharmacogenomics analyses genes encoding drug-metabolising enzymes — principally the CYP450 enzyme family (CYP2D6, CYP2C19, CYP2C9, CYP3A4/5) — alongside drug transporters and receptor targets to predict individual drug response, optimal dosing ranges, and adverse reaction risk across hundreds of commonly prescribed medications.
Who Should Seek This Consultation
- Patients currently on multiple medications (polypharmacy) | Those who have previously experienced adverse drug reactions | Oncology patients requiring chemotherapy dose optimisation | Patients with psychiatric conditions requiring antidepressant or antipsychotic guidance | Physicians seeking to personalise prescribing for complex patients
What You Receive
Comprehensive pharmacogenomics advisory report | Drug-gene interaction analysis across current medication list | Prescribing guidance brief for treating physician | Personalised medication optimisation action plan | Follow-up advisory support
Early Neurodegenerative Disease Screening Advisory
Pioneer Access to GDI's Alzheimer's Early Detection R&D Programme
No diagnostic test currently exists for early Alzheimer's disease. GDI is working to change that — and you can be among the first to access our R&D programme. Our Early Neurodegenerative Screening Advisory provides expert consultation on current genomic risk factors for Alzheimer's and other neurodegenerative diseases, alongside exclusive access to GDI's proprietary early detection research — a world-first initiative with the potential to transform outcomes for millions.
The Science
GDI's proprietary R&D programme focuses on identifying genomic and molecular biomarkers — including APOE ε4 variants, tau pathway markers, and novel NGS-identified loci — associated with neurodegenerative disease onset. If this technology achieves clinical validation, it could enable Alzheimer's detection years before symptoms manifest, fundamentally changing the treatment landscape globally.
Who Should Seek This Consultation
Individuals with family history of Alzheimer's disease or dementia | Those experiencing early cognitive symptoms (memory lapses, word-finding difficulty) | Neurology researchers and clinicians seeking R&D collaboration | Families seeking proactive genomic risk assessment | Anyone who wants to understand their neurodegenerative disease risk profile
What You Receive
- Current genomic risk assessment advisory report | APOE and associated variant analysis guidance | GDI R&D programme update and participation brief | Proactive monitoring and lifestyle modification plan | Specialist neurology referral pathway
What You Receive
- Institutional Strategic Roadmap for Precision Medicine.
- Compliance Audit & Gap Analysis Report.
- Technical Specifications for Genomic Infrastructure.
- Physician Engagement & Clinical Utility Guidelines.